ELIXIRON IMMUNOTHERAPEUTICS
Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain... phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
ELIXIRON IMMUNOTHERAPEUTICS
Social Links:
Industry:
Biotechnology
Founded:
2017-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.elixiron.com
Total Employee:
11+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Microsoft Exchange Online Office 365 Mail ASP.NET IIS ASP.NET 4.0 GoDaddy SSL
Current Employees Featured
Founder
Investors List
Alzheimer's Association
Alzheimer's Association investment in Grant - Elixiron Immunotherapeutics
Pangu Venture Capital
Pangu Venture Capital investment in Series A - Elixiron Immunotherapeutics
Mega International Commercial Bank
Mega International Commercial Bank investment in Series A - Elixiron Immunotherapeutics
China Development Industrial Bank (CDIB)
China Development Industrial Bank (CDIB) investment in Series A - Elixiron Immunotherapeutics
DCI Partners
DCI Partners investment in Series A - Elixiron Immunotherapeutics
Fubon Financial Holdings
Fubon Financial Holdings investment in Series A - Elixiron Immunotherapeutics
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation investment in Series A - Elixiron Immunotherapeutics
Official Site Inspections
http://www.elixiron.com Semrush global rank: 7 M Semrush visits lastest month: 646
- Host name: 47.243.30.47
- IP address: 47.243.30.47
- Location: San Mateo United States
- Latitude: 37.5517
- Longitude: -122.33
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94402
More informations about "Elixiron Immunotherapeutics"
Elixiron Immunotherapeutics Inc.
Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy; July 12, 2022; Elixiron dives into IFNγ and CSF-1R with pathway …See details»
Elixiron Immunotherapeutics - Crunchbase Company …
Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our …See details»
安立玺荣(上海)生物医药科技有限公司 - Elixiron
Feb 7, 2020 安立玺荣（上海）生物医药科技有限公司 上海市浦东新区荣科路118号凯瑞大厦3号楼 02A102. 投资人关系专用信箱: [email protected] 媒体联络信箱: [email protected] …See details»
Elixiron Immunotherapeutics - LinkedIn
Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company ...See details»
Elixiron Immunotherapeutics - Funding, Financials, Valuation
Elixiron Immunotherapeutics is a company developing therapeutics for cancer, rare, and inflammatory disorders. Search Crunchbase. Start Free Trial . Chrome Extension. ... How …See details»
Elixiron Immunotherapeutics - VentureRadar
"Elixiron employs advances in reverse translational medicine approaches to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary …See details»
Elixiron Immunotherapeutics Company Profile - Craft
Elixiron Immunotherapeutics is a biotechnology company that develops therapies for immunological and degenerative diseases. It applies translational medicine and clinical …See details»
Elixiron Immunotherapeutics - Contacts, Employees, Board …
Elixiron Immunotherapeutics is a company developing therapeutics for cancer, rare, and inflammatory disordersSee details»
Elixiron Immunotherapeutics Receives Grant From the Alzheimer's ...
SAN FRANCISCO, July 12, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage drug development company announced today that it has received a new grant from the …See details»
安立璽榮生醫股份有限公司 - Elixiron
Feb 7, 2020 安立璽榮生醫股份有限公司. 台北市南港區忠孝東路7段508號16樓之3. 投資人關係專用信箱: [email protected]. 媒體聯絡信箱: [email protected] 加入我們: …See details»
Elixiron - PharmaBoardroom
Selecting targets from clinical observations like these, and utilizing our proprietary human single B cell cloning technology platform, Elixiron is developing originally human anti-cytokine …See details»
Elixiron Immunotherapeutics Announces Orphan Drug …
Sep 6, 2022 Elixiron Immunotherapeutics is developing innovative immunotherapies to address unmet needs in rare and immunological diseases. Besides EI‑001, Elixiron has an orally …See details»
Elixiron Immunotherapeutics - Updates, News, Events
Mar 28, 2024 Elixiron Immunotherapeutics is a company developing therapeutics for cancer, rare, and inflammatory disordersSee details»
Elixiron Immunotherapeutics Inc.
Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy; July 12, 2022; Elixiron dives into IFNγ and CSF-1R with pathway …See details»
Elixiron Immunotherapeutics, Inc. (安立玺荣（上海）生物医药科技 …
了解Elixiron Immunotherapeutics, Inc. (安立玺荣（上海）生物医药科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的3项临床试验, 35篇新闻和1篇文献，疾病领域:肿瘤，神经系 …See details»
OPPORTUNITIES - ELIXIRON INC
An owner partner is accountable for the overall handling and running of a profitable organization, framing a business plan, attending international seminars and networking with several offices …See details»
ELIXIRON INC
Slowly I built a separate entity with my own efforts and hardwork – Elixiron Inc. Believe and trust in yourself and observe the change that comes your way. Roshni. Myself Ahamed Altaf …See details»
Elixiron Immunotherapeutics - Tech Stack, Apps, Patents
Nov 10, 2024 Organization. Elixiron Immunotherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech …See details»
Elixiron Immunotherapeutics - Crunchbase
Companies like Elixiron Immunotherapeutics include Sirnaomics, Arrakis Therapeutics, and Apellis Pharmaceuticals. Apellis Pharmaceuticals Waltham , Massachusetts , United States …See details»
A POTENT AND SELECTIVE CFMS INHIBITOR EI-1071 INHIBITS …
A POTENT AND SELECTIVE CFMS INHIBITOR EI-1071 INHIBITS CSF1R SIGNALING AND REGULATES THE TUMOR-ASSOCIATED MACROPHAGES Hung-Kai Chen1, Huey-Wen …See details»